Biotech Isis Pharmaceuticals (ISIS) saw its shares rise Thursday after the company reported positive midstage data on a rare-disease drug candidate. Its development partner Biogen (BIIB) also got a lift. Isis stock was up 3% in midday trading in the stock market today, near 68.50. Earlier, Isis stock rose as high a 71.50, to a nearly three-month high. Biogen stock was up 1.5% in midday trading Thursday. Isis reported on a phase-two trial of
Biotech Isis Pharmaceuticals (ISIS) on Monday announced a licensing deal with German pharma giant Bayer (BAYRY) to develop Isis’ new thrombosis drug, sending its stock up as much as 6.8%. Bayer agreed to pay $100 million upfront and a $55 million milestone payment once Isis completes its phase-two study of ISIS-FXI Rx, an anticlotting drug being studied in patients with compromised kidney function. The company’s press release said it is eligible
Biotech Isis Pharmaceuticals (ISIS) leapt 10% to a new high above 68 In the stock market today after it signed a licensing deal with Johnson & Johnson worth up to $835 million. J&J’s (JNJ) Janssen Biotech arm agreed to pay $35 million upfront and up to $800 million in milestone payments to develop drugs for autoimmune disorders of the gastrointestinal tract using Isis’ RNA-targeting platform. Such GI disorders have already filled Janssen’s coffers